The role of pulmonary vascular contractile protein expression in pulmonary arterial hypertension

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 147-155

  Konik, Ewa A ^a   Han, Young Soo ^a   Brozovich, Frank V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Myosin light chain phosphatase; Myosin phosphatase targeting subunit 1; Nitric oxide; Nonmuscle myosin; Smooth muscle myosin; Vascular reactivity

Indexed keywords

ANGIOPOIETIN 2; CONTRACTILE PROTEIN; MYOSIN; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; NONMUSCLE MYOSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; LUNG ARTERY; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; VASOCONSTRICTION; VASODILATATION;

MYOSIN LIGHT CHAIN PHOSPHATASE; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; NITRIC OXIDE; NONMUSCLE MYOSIN; SMOOTH MUSCLE MYOSIN; VASCULAR REACTIVITY;

ACETYLCHOLINE; ANIMALS; CONTRACTILE PROTEINS; HYPERTENSION, PULMONARY; LEUCINE ZIPPERS; LUNG; MALE; MYOSIN HEAVY CHAINS; PROTEIN PHOSPHATASE 1; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASODILATION;

EID: 84887196546     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.10.009     Document Type: Article

References (58)

1. Sitbon O., Humbert M., Jaïs X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
2. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
3. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216-223.
4. Thenappan T., Shah S.J., Rich S., Tian L., Archer S.L., Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010, 35:1079-1087.
5. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
6. Sakao S., Taraseviciene-Stewart L., Lee J.D., Wood K., Cool C.D., Voelkel N.F. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005, 19:1178-1180.
7. Morrell N.W., Yang X., Upton P.D., Jourdan K.B., Morgan N., Sheares K.K., et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001, 104:790-795.
8. McMurtry M.S., Archer S.L., Altieri D.C., Bonnet S., Haromy A., Harry G., et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005, 115:1479-1491.
9. Archer S.L., Weir E.K., Wilkins M.R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010, 121:2045-2066.
10. Hartshorne D.J. Myosin phosphatase: subunits and interactions. Acta Physiol Scand 1998, 164:483-493.
11. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003, 83:1325-1358.
12. Gong M.C., Cohen P., Kitazawa T., Ikebe M., Masuo M., Somlyo A.P., et al. Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J Biol Chem 1992, 267:14662-14668.
13. Khatri J.J., Joyce K.M., Brozovich F.V., Fisher S.A. Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem 2001, 276:37250-37257.
14. Huang Q.Q., Fisher S.A., Brozovich F.V. Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem 2004, 279:597-603.
15. Karim S.M., Rhee A.Y., Given A.M., Faulx M.D., Hoit B.D., Brozovich F.V. Vascular reactivity in heart failure: role of myosin light chain phosphatase. Circ Res 2004, 95:612-618.
16. Chen F.C., Ogut O., Rhee A.Y., Hoit B.D., Brozovich F.V. Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. J Mol Cell Cardiol 2006, 41:488-495.
17. Payne M.C., Zhang H.-Y., Shirasawa Y., Koga Y., Ikebe M., Benoit J.N., et al. Dynamic changes in expression of myosin phosphatase in a model of portal hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1801-H1810.
18. Lu Y., Zhang H., Gokina N., Mandala M., Sato O., Ikebe M., et al. Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy. Am J Physiol Cell Physiol 2008, 294:C564-C571.
19. Wang F., Kovacs M., Hu A., Limouze J., Harvey E.V., Sellers J.R. Kinetic mechanism of non-muscle myosin IIB: functional adaptations for tension generation and maintenance. J Biol Chem 2003, 278:27439-27448.
20. Kovács M., Wang F., Hu A., Zhang Y., Sellers J.R. Functional divergence of human cytoplasmic myosin II: kinetic characterization of the non-muscle IIA isoform. J Biol Chem 2003, 278:38132-38140.
21. Yuen S.L., Ogut O., Brozovich F.V. Nonmuscle myosin is regulated during smooth muscle contraction. Am J Physiol Heart Circ Physiol 2009, 297:H191-H199.
22. Stenmark K.R., Meyrick B., Galie N., Mooi W.J., McMurtry I.F. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1013-L1032.
23. Urboniene D., Haber I., Fang Y.-H., Thenappan T., Archer S.L. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010, 299:L401-L412.
24. Yeager M.E., Reddy M.B., Nguyen C.M., Colvin K.L., Ivy D.D., Stenmark K.R. Activation of the unfolded protein response is associated with pulmonary hypertension. Pulm Circ 2012, 2:229-240.
25. Han Y.S., Brozovich F.V. Altered reactivity of tertiary mesenteric arteries following acute myocardial ischemia. J Vasc Res 2013, 50:100-108.
26. Given A.M., Ogut O., Brozovich F.V. MYPT1 mutants demonstrate the importance of aa 888-928 for the interaction with PKGIalpha. Am J Physiol Cell Physiol 2007, 292:C432-C439.
27. Jones J.E., Mendes L., Rudd M.A., Russo G., Loscalzo J., Zhang Y.-Y. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 2002, 283:H364-H371.
28. Morano I., Chai G.X., Baltas L.G., Lamounier-Zepter V., Lutsch G., Kott M., et al. Smooth-muscle contraction without smooth-muscle myosin. Nat Cell Biol 2000, 2:371-375.
29. Löfgren M., Ekblad E., Morano I., Arner A. Nonmuscle myosin motor of smooth muscle. J Gen Physiol 2003, 121:301-310.
30. Langleben D., Szarek J.L., Coflesky J.T., Jones R.C., Reid L.M., Evans J.N. Altered artery mechanics and structure in monocrotaline pulmonary hypertension. J Appl Physiol 1988, 65:2326-2331.
31. Griffith S.L., Rhoades R.A., Packer C.S. Pulmonary arterial smooth muscle contractility in hypoxia-induced pulmonary hypertension. J Appl Physiol 1994, 77:406-414.
32. Golomb E., Ma X., Jana S.S., Preston Y.A., Kawamoto S., Shoham N.G., et al. Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family. J Biol Chem 2003, 279:2800-2808.
33. Packer C.S., Roepke J.E., Oberlies N.H., Rhoades R.A. Myosin isoform shifts and decreased reactivity in hypoxia-induced hypertensive pulmonary arterial muscle. Am J Physiol 1998, 274:L775-L785.
34. Siegman M.J., Davidheiser S., Mooers S.U., Butler T.M. Structural limits on force production and shortening of smooth muscle. J Muscle Res Cell Motil 2013, 34:43-60.
35. Ogut O., Yuen S.L., Brozovich F.V. Regulation of the smooth muscle contractile phenotype by nonmuscle myosin. J Muscle Res Cell Motil 2007, 28:409-414.
36. Tullio A.N., Accili D., Ferrans V.J., Yu Z.X., Takeda K., Grinberg A., et al. Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc Natl Acad Sci U S A 1997, 94:12407-12412.
37. Kovács M., Thirumurugan K., Knight P.J., Sellers J.R. Load-dependent mechanism of nonmuscle myosin 2. Proc Natl Acad Sci U S A 2007, 104:9994-9999.
38. Rhee A.Y., Ogut O., Brozovich F.V. Nonmuscle myosin, force maintenance, and the tonic contractile phenotype in smooth muscle. Pflugers Arch 2006, 452:766-774.
39. McLean J.R., Twarog B.M., Bergofsky E.H. The adrenergic innervation of pulmonary vasculature in the normal and pulmonary hypertensive rat. J Auton Nerv Syst 1985, 14:111-123.
40. Kummer W. Pulmonary vascular innervation and its role in responses to hypoxia: size matters!. Proc Am Thorac Soc 2011, 8:471-476.
41. Yuen S., Ogut O., Brozovich F.V. MYPT1 protein isoforms are differentially phosphorylated by protein kinase G. J Biol Chem 2011, 286:37274-37279.
42. Altiere R.J., Olson J.W., Gillespie M.N. Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension. J Pharmacol Exp Ther 1986, 236:390-395.
43. Coflesky J.T., Jones R.C., Reid L.M., Evans J.N. Mechanical properties and structure of isolated pulmonary arteries remodeled by chronic hyperoxia. Am Rev Respir Dis 1987, 136:388-394.
44. Madden J.A., Keller P.A., Effros R.M., Seavitte C., Choy J.S., Hacker A.D. Responses to pressure and vasoactive agents by isolated pulmonary arteries from monocrotaline-treated rats. J Appl Physiol 1994, 76:1589-1593.
45. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
46. Singh D.K., Sarkar J., Raghavan A., Reddy S.P., Raj J.U. Hypoxia modulates the expression of leucine zipper-positive MYPT1 and its interaction with protein kinase G and Rho kinases in pulmonary arterial smooth muscle cells. Pulm Circ 2011, 1:487-498.
47. Fisher S.A. Vascular smooth muscle phenotypic diversity and function. Physiol Genomics 2010, 42A:169-187.
48. Dou D., Ma H., Zheng X., Ying L., Guo Y., Yu X., et al. Degradation of leucine zipper-positive isoform of MYPT1 may contribute to development of nitrate tolerance. Cardiovasc Res 2010, 86:151-159.
49. Ararat E., Brozovich F.V. Losartan decreases p42/44 MAPK signaling and preserves LZ+MYPT1 expression. PLoS ONE 2009, 4:e5144.
50. Marsboom G., Archer S.L. Pathways of proliferation: new targets to inhibit the growth of vascular smooth muscle cells. Circ Res 2008, 103:1047-1049.
51. McGoon M., Gutterman D., Steen V., Barst R., McCrory D.C., Fortin T.A., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:14S-34S.
52. Jeffery T.K., Wanstall J.C. Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: comparative effects on pulmonary vascular structure and function. Br J Pharmacol 1999, 128:1407-1418.
53. Okada M., Harada T., Kikuzuki R., Yamawaki H., Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 2009, 111:193-200.
54. Tavli T., Gocer H. Effects of cilazapril on endothelial function and pulmonary hypertension in patients with congestive heart failure. Jpn Heart J 2002, 43:667-674.
55. Kanno S., Wu Y.J., Lee P.C., Billiar T.R., Ho C. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 2001, 104:945-950.
56. Bradford C.N., Ely D.R., Raizada M.K. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr Hypertens Rep 2010, 12:212-219.
57. Schermuly R.T., Stasch J.-P., Pullamsetti S.S., Middendorff R., Muller D., Schluter K.-D., et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008, 32:881-891.
58. Lang M., Kojonazarov B., Tian X., Kalymbetov A., Weissmann N., Grimminger F., et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS ONE 2012, 7:e43433.